DK1313467T3 - Hidtil ukendte farmaceutiske præparater til indgivelse af N-0923 - Google Patents

Hidtil ukendte farmaceutiske præparater til indgivelse af N-0923

Info

Publication number
DK1313467T3
DK1313467T3 DK01969617T DK01969617T DK1313467T3 DK 1313467 T3 DK1313467 T3 DK 1313467T3 DK 01969617 T DK01969617 T DK 01969617T DK 01969617 T DK01969617 T DK 01969617T DK 1313467 T3 DK1313467 T3 DK 1313467T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical compositions
administration
rotigotine
new pharmaceutical
patient
Prior art date
Application number
DK01969617T
Other languages
Danish (da)
English (en)
Inventor
Markus Thelen
Stephan Rimpler
Sabine Grapatin
Cliff Krein
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of DK1313467T3 publication Critical patent/DK1313467T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01969617T 2000-08-24 2001-08-21 Hidtil ukendte farmaceutiske præparater til indgivelse af N-0923 DK1313467T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10041479A DE10041479A1 (de) 2000-08-24 2000-08-24 Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923

Publications (1)

Publication Number Publication Date
DK1313467T3 true DK1313467T3 (da) 2006-02-27

Family

ID=7653577

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01969617T DK1313467T3 (da) 2000-08-24 2001-08-21 Hidtil ukendte farmaceutiske præparater til indgivelse af N-0923

Country Status (12)

Country Link
US (1) US8604076B2 (ja)
EP (1) EP1313467B1 (ja)
JP (1) JP4592250B2 (ja)
CN (1) CN1531428A (ja)
AT (1) ATE306262T1 (ja)
AU (1) AU2001289820A1 (ja)
CA (1) CA2420061C (ja)
DE (2) DE10041479A1 (ja)
DK (1) DK1313467T3 (ja)
ES (1) ES2250475T3 (ja)
PL (1) PL365940A1 (ja)
WO (1) WO2002015903A2 (ja)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
ES2239196T3 (es) * 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
CN1762495B (zh) * 2004-09-21 2011-04-06 山东绿叶制药有限公司 含有多巴胺受体激动剂类药物的长效缓释制剂及其制备工艺
KR20070059161A (ko) * 2004-09-21 2007-06-11 산동 루예 파마슈티칼 컴파니 리미티드 도파민 수용체 효능제를 함유하는 장시간 작용 서방성 제제및 그 제조방법
EA017896B1 (ru) 2006-04-06 2013-04-30 Нюпэф Инк. Имплантаты для лечения состояний, ассоциируемых с допамином
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
AU2008215659B2 (en) * 2007-02-16 2012-11-01 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
WO2009053697A1 (en) * 2007-10-26 2009-04-30 Pliva Hrvatska D.O.O. Polymorphic forms of ( s ) -rotigotine hydrochloride
WO2009063171A1 (en) * 2007-11-16 2009-05-22 Pliva Hrvatska D.O.O. Novel rotigotine salts
WO2009063170A1 (en) * 2007-11-16 2009-05-22 Pliva Hrvatska D.O.O. Preparation of crystalline rotigotine base
MX2010005925A (es) 2007-11-28 2010-08-02 Ucb Pharma Gmbh Nueva forma polimorfico de rotigotina y proceso para la produccion.
EP2281559A1 (en) * 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
EA025584B1 (ru) 2009-12-22 2017-01-30 ЮСиБи ФАРМА ГМБХ Поливинилпирролидон для стабилизации твердой дисперсии некристаллической формы ротиготина
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
WO2013075823A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
WO2015001012A1 (de) 2013-07-03 2015-01-08 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches system mit elektronischem bauteil
WO2015177204A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
EP3145503A1 (en) 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Method for adjusting the release of active agent in a transdermal delivery system
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
WO2018096560A1 (en) * 2016-11-23 2018-05-31 Cipla Limited Long acting depot formulation for the continuous dopaminergic stimulation
WO2019036624A1 (en) 2017-08-17 2019-02-21 Gu Zi Qiang MONOAMINE PAMOATE SALT TYPE ANTI-PARKINSON AGENTS, PROCESS FOR PREPARING AND USING SAME
DE102017124627A1 (de) 2017-10-20 2019-04-25 Amw Gmbh Transdermales Darreichungssystem enthaltend einen Dopaminagonisten
US20190374534A1 (en) 2018-06-08 2019-12-12 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising pergolide
WO2023115311A1 (zh) * 2021-12-21 2023-06-29 南京清普生物科技有限公司 一种缓释制剂组合物

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2992165A (en) * 1957-10-01 1961-07-11 Robert E Thompson Method of potentiating acth preparations
US2964448A (en) * 1959-01-27 1960-12-13 Anschel Joachim Relaxin composition and process for preparing same
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
GB2105589B (en) 1981-09-11 1985-10-23 Wellcome Found Injectable suspensions containing maleic acid or a salt thereof as a stabilising agent
US4465692A (en) * 1982-01-03 1984-08-14 Nelson Research & Development Company Selective D-2 dopamine receptor agonist
US4722933A (en) * 1985-12-20 1988-02-02 Nelson Research & Development Co. Substituted 2-aminotetralins
US5177112A (en) * 1983-01-03 1993-01-05 Whitby Research, Inc. Substituted 2-aminotetralins
US5256661A (en) * 1983-01-03 1993-10-26 Whitby Research, Inc. Substituted 2-aminotetralins and pharmaceutical use
US4743618A (en) * 1983-01-03 1988-05-10 Nelson Research & Development Co. Substituted 2-aminotetralins
US4657925A (en) * 1984-08-13 1987-04-14 Nelson Research & Development Co. Method and compositions for reducing the intraocular pressure of mammals
US4564628A (en) * 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
US4540691A (en) * 1984-04-13 1985-09-10 Nelson Research & Development Co. Dopamine agonists and use thereof
DE3479314D1 (en) 1984-05-22 1989-09-14 Nelson Res & Dev Substituted 2-aminotetralins and processes for synthesis
US4885308A (en) * 1984-08-13 1989-12-05 Nelson Research & Development Co. Method and compositions for treatment of parkinsonism syndrome in mammals
US4772933A (en) * 1986-02-03 1988-09-20 General Electric Company Method for compensating operationally-induced defects and semiconductor device made thereby
JPH0816066B2 (ja) * 1986-07-18 1996-02-21 エーザイ株式会社 持続性薬効製剤
ES2005164A6 (es) 1987-04-14 1989-03-01 Lilly S A E Un procedimiento para la produccion de derivados de tiofen-2-carboxamida.
ES2005163A6 (es) 1987-04-14 1989-03-01 Lilly S A E Un procedimiento para la produccion de derivados de tiofen-2-carboxamida.
WO1989003671A1 (en) * 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Sustained-release preparation
US4913699A (en) 1988-03-14 1990-04-03 Parsons James S Disposable needleless injection system
US4913669A (en) * 1988-09-06 1990-04-03 Young Ronald G Boat propulsion apparatus
US5234945A (en) * 1989-05-09 1993-08-10 Whitby Research, Inc. Method of producing body weight and food intake using a dopamine D2 receptor agonist
AU5439890A (en) * 1989-05-09 1990-11-29 Whitby Research, Inc. A method of reducing body weight and food intake using a dopamine d2 receptor agonist
US5545755A (en) * 1989-05-31 1996-08-13 The Upjohn Company Therapeutically useful 2-aminotetralin derivatives
IE64620B1 (en) 1989-06-01 1995-08-23 Bimeda Res Dev Ltd A veterinary preparation
US5486611A (en) * 1989-07-13 1996-01-23 The Upjohn Company Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives
EP0507863A4 (en) * 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5633376A (en) * 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
US5176643A (en) * 1991-04-29 1993-01-05 George C. Kramer System and method for rapid vascular drug delivery
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
RU2109509C1 (ru) 1991-12-24 1998-04-27 Яманути Фармасьютикал Ко., Лтд. Композиция для буккального введения лекарственного средства и способ ее получения
CA2095499A1 (en) * 1992-05-08 1993-11-09 Petrus J. M. Van Den Oetelaar Depot preparation
AU4312593A (en) 1992-05-18 1993-12-13 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease
US5989586A (en) 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5462743A (en) 1992-10-30 1995-10-31 Medipro Sciences Limited Substance transfer system for topical application
JPH06234631A (ja) * 1992-12-16 1994-08-23 Takeda Chem Ind Ltd フマギロール誘導体の安定医薬組成物
DE4325855A1 (de) 1993-08-02 1995-02-09 Boehringer Ingelheim Kg Neue Benzoesäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5382596A (en) * 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
GB9324018D0 (en) * 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
US5670501A (en) * 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
US5658955A (en) * 1994-11-01 1997-08-19 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of immune disorders
US5840062A (en) * 1995-11-08 1998-11-24 Gumaste; Anand V. Solid state fluid delivery system
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6166037A (en) * 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
US6169084B1 (en) * 1997-09-30 2001-01-02 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6066292A (en) * 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
HU226588B1 (en) * 1998-04-02 2009-04-28 Novartis Ag Method for stabilizing pharmaceutical compositions by special use an antioxidant
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
US6844368B1 (en) * 1998-12-22 2005-01-18 Edward Roberts Compounds useful in pain management
US6498196B1 (en) * 1998-12-22 2002-12-24 Edward Roberts Compounds useful in pain management
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
EP1232152B1 (en) 1999-11-23 2004-02-04 Aderis Pharmaceuticals, Inc. Improved process for preparing nitrogen-substituted aminotetralins
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10055742B4 (de) * 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
FR2829028B1 (fr) * 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
WO2003088958A2 (en) * 2002-04-18 2003-10-30 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson’s disease
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
CA2503381A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
ES2239196T3 (es) * 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
EP1708706A1 (en) * 2004-01-22 2006-10-11 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
BRPI0514015A (pt) 2004-08-02 2008-05-27 Sanol Arznei Schwarz Gmbh carboxamidas da indolizina e seus derivados aza e diaza
DE102004054634A1 (de) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
MX2010005925A (es) * 2007-11-28 2010-08-02 Ucb Pharma Gmbh Nueva forma polimorfico de rotigotina y proceso para la produccion.

Also Published As

Publication number Publication date
PL365940A1 (en) 2005-01-24
DE10041479A1 (de) 2002-03-14
CA2420061A1 (en) 2003-02-20
WO2002015903A2 (de) 2002-02-28
DE50107705D1 (de) 2006-02-23
US8604076B2 (en) 2013-12-10
JP2004520269A (ja) 2004-07-08
AU2001289820A1 (en) 2002-03-04
CA2420061C (en) 2012-12-11
US20030166709A1 (en) 2003-09-04
EP1313467A2 (de) 2003-05-28
ES2250475T3 (es) 2006-04-16
JP4592250B2 (ja) 2010-12-01
CN1531428A (zh) 2004-09-22
EP1313467B1 (de) 2005-10-12
ATE306262T1 (de) 2005-10-15
WO2002015903A3 (de) 2002-05-23

Similar Documents

Publication Publication Date Title
DK1313467T3 (da) Hidtil ukendte farmaceutiske præparater til indgivelse af N-0923
HK1076605A1 (en) Formulations
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
HRP20040354B1 (en) Novel cyclosporin analog microemulsion preconcentrates
WO2001044271A3 (en) Daptomycin analogs and their use as antibacterial agents
EA200300937A1 (ru) Оральная фармацевтическая композиция цефподоксима проксетила
MXPA02006029A (es) Lipopeptidos novedosos como agentes antibacterianos.
EE200100485A (et) Uudsed ühendid ja kompositsioonid proteaasi inhibiitoritena
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
MXPA04000456A (es) Analogos de prostaglandina como agonistas del receptor ep4.
MXPA02006030A (es) Lipopeptidos como agentes antibacterianos.
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
BR0100949A (pt) Inibição da degradação oxidativa de formulaçõesfarmacêuticas
BR0008509A (pt) Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
SE9901077D0 (sv) Novel use
ATE380174T1 (de) Arginin-mimetika als faktor xa-inhibitoren
BR0315663A (pt) Formulações de depósito de agentes ativos de aril-heterocìclicos na forma de uma suspensão
BR0009674A (pt) Composto, droga, e, uso de composto
SE9801494D0 (sv) Novel use
RS50764B (sr) Farmaceutska kompozicija koja uključuje so mirtazapina
MXPA06000636A (es) Formulaciones semi-solidas para la administracion oral de taxoides.
TNSN06013A1 (en) Semi-solid systems containing azetidine derivatives
BR0208655A (pt) Composição farmacêuticas
YU87501A (sh) Farmaceutski kompleksi